<DOC>
	<DOCNO>NCT02018458</DOCNO>
	<brief_summary>The primary objective study determine safety feasibility combine cyclin B1/WT-1/CEF ( antigen ) -loaded DC vaccination preoperative chemotherapy . The secondary objective trial determine pathologic complete response rate ; disease-free survival ; ass immune biomarkers immunity ( antigen-specific CD8+ T cell immunity TH2 T cell ) breast cancer biopsy specimens blood sample patient receive DC vaccination ; assess feasibility immunize LA TNBC ER+/HER2- BC patient patient-specific tumor antigen .</brief_summary>
	<brief_title>Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine Treat Breast Cancer</brief_title>
	<detailed_description>Recent study show human breast cancer immunogenic , enhance immune effector function already present may augment cytotoxic effect standard therapy . vaccination remain attractive strategy expect inducement therapeutic T cell immunity ( effector T cell ) protective T cell immunity ( tumor-specific memory T cell control tumor relapse ) . Several clinical study demonstrate immunity tumor antigen enhance cancer patient vaccination ex vivo-generated tumor antigen-loaded dendritic cell ( DCs ) . This strategy capitalize unique capacity DCs prime lymphocyte regulate maintain immune response . Our goal boost T cell immunity target breast cancer utilize tumor antigen-loaded DC vaccine , enhance chemotherapy effectiveness decrease tumor metastagenicity , decrease recurrence rate LA TNBC ER+/HER2- BC . Patients treated combination antigen-loaded DC vaccination along standard preoperative chemotherapy , improve immunogenicity increase pCR rate achieve standard therapy . The trial consist 2 patient cohort : TNBC ER+/HER2- BC .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>A patient consider enrollment study follow criterion meet : 1 . Female patient ≥18 year age . 2 . Have either : 1. locally advanced TNBC define invasive ductal cancer ; ER tumor &lt; 10 % tumor nuclei immunoreactive ; PR tumor &lt; 10 % tumor nuclei immunoreactive ; T3 T4 disease , regardless nodal status ( T2 disease eligible positive lymph node present physical exam image evaluation histological evaluation , OR 2 . Highrisk ER+ breast cancer define grade 3 invasive ductal mixed ductal/lobular cancer , grade 2 Ki67 ≥20 % ; node positive evidenced physical exam image evaluation histological evaluation . 3 . HER2 negative breast cancer . If HER2 , define follow : 1 . FISHnegative ( FISH ratio &lt; 2.0 ) , 2 . IHC 01+ , 3 . IHC 2+ AND FISHnegative ( FISH ratio &lt; 2.0 ) 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 5 . Adequate hematologic function , define : 1 . Absolute neutrophil count ( ANC ) &gt; 1500/mm3 2 . Platelet count ≥100,000/mm3 3 . Hemoglobin &gt; 9 g/dL ( absence red blood cell transfusion ) 6 . Adequate liver function , define : a. AST ALT ≤2.5 x upper limit normal ( ULN ) b . Total bilirubin ≤1.5 x ULN 7 . Adequate renal function , define : a. Serum creatinine ≤1.5 x ULN calculate creatinine clearance ≥60 ml/min 8 . Patients previous history invasive cancer ( include breast cancer ) eligible definitive treatment complete 5 year prior initiate current study treatment , evidence recurrent disease . 9 . Eligible treatment paclitaxel , doxorubicin , cyclophosphamide carboplatine . 10.Patient must accessible treatment followup . 11.Patients must willing undergo research biopsy obtain breast cancer tissue whole exome sequence evaluation tumor immune microenvironment . 12.All patient must able understand investigational nature study give write informed consent prior study entry . A patient ineligible inclusion study follow criterion meet : 1 . Evidence metastatic disease bone scan CT scan chest/abdomen ( PET CT scan ) . Patients intrathoracic metastatic adenopathy eligible . 2 . Active infection unexplained fever &gt; 38.5°C screening . 3 . Active infection include viral hepatitis HIV . 4 . Active asthma condition require steroid therapy . 5 . Autoimmune disease include lupus erythematosus rheumatoid arthritis . Topical inhale corticosteroid allow . 6 . Patients currently receive receive previous systemic therapy breast cancer ( eg , chemotherapy , antibody therapy , target agent ) .The use LHRH agonist chemotherapy premenopausal woman wish preserve ovarian function allow , require . 7 . Women pregnant lactating . All patient reproductive potential must agree use effective contraception time study entry least 3 month last administration study drug . 8 . Have NYHA Class III IV CHF LVEF &lt; 55 % . Patients significant cardiac disease history within 1 year ventricular arrhythmia require medication also exclude . 9 . Patients severe and/or uncontrolled medical condition condition could affect participation : 1. severe impair lung function define spirometry DLCO 50 % normal predict value and/or O2 saturation 88 % less rest room air 2. uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN 3. liver disease cirrhosis severe hepatic impairment ( ChildPugh class C ) . 10 . History disease , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug , might affect interpretation result study , render patient high risk treatment complication . 11 . Any investigational anticancer treatment participate study . 12 . Any cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Dendritic cell vaccine</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Carboplatin</keyword>
</DOC>